Literature DB >> 9780250

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.

L D Loomis-Price1, J H Cox, J R Mascola, T C VanCott, N L Michael, T R Fouts, R R Redfield, M L Robb, B Wahren, H W Sheppard, D L Birx.   

Abstract

Human immunodeficiency virus (HIV)-1-infected rapid and slow progressors showed differential humoral responses against HIV envelope peptides and proteins early in infection. Sera from slow progressors reacted more strongly with short envelope peptides modeling gp160NL4-3, predominantly in gp41. Reactivity to six peptides (in constant regions C3, C4, and C5 of gp120 and in gp41) correlated with slower progression. In a novel association, reactivity to three peptides (in constant regions C1 and C3 and variable region V3 of gp120) correlated with faster progression. Envelope peptide reactivity correlated with subsequent course of disease progression as strongly as did reactivity to gag p24. Patients heterozygous for 32-bp deletions in the CCR5 coreceptor reacted more frequently to an epitope in gp41. Rapid progressors had greater gp120 native-to-denatured binding ratios than did slow progressors. While antibody-dependent cellular cytotoxicity against gp120 did not strongly differentiate the groups, slow progressors showed a broader neutralization pattern against 5 primary virus isolates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780250     DOI: 10.1086/314436

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.

Authors:  T Beaumont; S Broersen; A van Nuenen; H G Huisman; A M de Roda Husman; J L Heeney; H Schuitemaker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.

Authors:  T C VanCott; J R Mascola; L D Loomis-Price; F Sinangil; N Zitomersky; J McNeil; M L Robb; D L Birx; S Barnett
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 6.  Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

Authors:  Yi Xiao; Xiaonan Dong; Ying-Hua Chen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication.

Authors:  S Goldstein; C R Brown; H Dehghani; J D Lifson; V M Hirsch
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5.

Authors:  Houman Dehghani; Bridget A Puffer; Robert W Doms; Vanessa M Hirsch
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.

Authors:  Anne Piantadosi; Dana Panteleeff; Catherine A Blish; Jared M Baeten; Walter Jaoko; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.